Novartis announced two global licensing and collaboration agreements, including a deal with SciNeuro Pharmaceuticals for a de novo anti‑amyloid beta antibody program targeting Alzheimer’s disease. Novartis will collaborate on early development and then assume full responsibility for development and commercialization; SciNeuro will receive $165 million upfront plus up to $1.5 billion in milestones. Separately, Novartis licensed peptide cancer assets from Zonsen PepLib. Company executives framed the transactions as strategic additions to neuroscience and oncology pipelines during JPM week, with Novartis citing regulatory review requirements (Hart‑Scott‑Rodino filings) and routine closing conditions before final consummation. Novartis emphasized the deals’ fit with its R&D priorities and the expectation that in‑house capabilities can accelerate late preclinical and clinical development to regulatory submissions.